DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention.

Abstract

Cancer is a leading cause of death and major health concern worldwide. The animal and human studies support the presumption that inflammation directs the cancer initiation and progression. Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) are the key players in the inflammatory cascade contributing towards the angiogenesis, tumor cell invasiveness, and disruption in the pathways of cellular proliferation/apoptosis. Contemporary studies have particularized a promising role of COX-2 and 5-LOX inhibitors in cancer chemoprevention. The present review is a pursuit to define implications of dual COX-2 and 5-LOX (DuCLOX-2/5) inhibition on various aspects of cancer augmentation and chemoprevention.

• Authors: Swetlana Gautam, Subhadeep Roy, Mohd Nazam Ansari, Abdulaziz S Saeedan, Shubhini A Saraf, Gaurav Kaithwas
• Journal: Breast cancer (Tokyo, Japan) (Breast Cancer) Vol. 24 Issue 2 Pg. 180-190 (Mar 2017) ISSN: 1880-4233 [Electronic] Japan
• PMID: 27558792 (Publication Type: Journal Article, Review)

Chemical References

• Cyclooxygenase 2 Inhibitors
• Lipoxygenase Inhibitors
• Arachidonic Acid
• Arachidonate 5-Lipoxygenase
• Cyclooxygenase 2
• PTGS2 protein, human
• ALOX5 protein, human

Topics

• Animals
• Apoptosis (drug effects)
• Arachidonate 5-Lipoxygenase (metabolism)
• Arachidonic Acid (metabolism)
• Cyclooxygenase 2 (metabolism)
• Cyclooxygenase 2 Inhibitors (pharmacology)
• Humans
• Lipoxygenase Inhibitors (pharmacology)
• Molecular Targeted Therapy (methods)
• Neoplasms (blood supply, drug therapy, metabolism, pathology)
• Neovascularization, Pathologic (drug therapy, metabolism)